pacemaker

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.&nbsp;&nbsp; TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>

Post-dilatación de válvulas autoexpandibles

Balloon expandable vs Self-Expanding Valves: The Best Option for ViV-TAVR in Small Annuli

TAVR has consolidated as an increasingly valid alternative to treat failed surgical aortic valve bioprostheses. &nbsp; One of the major challenges it presents is patients with small annuli treated with a surgical bioprosthesis.&nbsp; There is little data available about this scenario. A few observational studies have shown what appears to be a hemodynamic advantage of<a href="https://solaci.org/en/2022/08/23/balloon-expandable-vs-self-expanding-valves-the-best-option-for-viv-tavr-in-small-annuli/" title="Read more" >...</a>

valve_in_valve-compressor

Surgical Bioprosthesis Deterioration: Is the Valve-in-Valve Technique a Good Option?

The use of surgical bioprostheses has significantly increased, and while they last 15 years or more, in cases where they fail (usually due to stenosis), the decision-making process is challenging. Transcatheter aortic valve replacement (TAVR) is a good alternative for this situation, although information on the subject matter is still scarce. Currently, the only available<a href="https://solaci.org/en/2022/08/18/surgical-bioprosthesis-deterioration-is-the-valve-in-valve-technique-a-good-option/" title="Read more" >...</a>

Discover SOLACI Congress Satellite Symposia

DISCOVER SOLACI CONGRESS’ SATELLITE SYMPOSIA Together with the attractive agenda of life and edited cases, joint sessions, and international guests, we will be holding 3 key activities characteristic of SOLACI Congresses: ProEducar Fellows course, 12th edition Pediatrics and Congenital Cardiomyopathies Symposium Nurses and Technicians Symposium Discover the complete program for each of these activities. We<a href="https://solaci.org/en/2022/07/30/discover-solaci-congress-satellite-symposia/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.&nbsp; Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.&nbsp; The bicaval<a href="https://solaci.org/en/2022/07/15/tricvalve-in-patients-with-severe-tricuspid-regurgitation-promising-results-at-6-months/" title="Read more" >...</a>

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular<a href="https://solaci.org/en/2022/06/29/safety-of-acetylcholine-in-the-cath-lab/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>

Experiencia de la cirugía

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>

EuroPCR 2022

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results.&nbsp; The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | TriCLASP, Evolution at 30 Days

Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.&nbsp; Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients<a href="https://solaci.org/en/2022/05/26/europcr-2022-triclasp-evolution-at-30-days/" title="Read more" >...</a>

Top